Nasdaq, Inc.

▲ Bull Case

• ◆Calypso wins the majority of FRTB platform decisions at Tier 1 banks, driving FinTech ARR to $2.5B+ by FY2027 and incremental revenue of $180–240M/year; combined with Verafin/FIS converting 300+ incremental bank clients and agentic AI premium tier monetization, the market re-rates to 23x EV/EBITDA — implying ~$130/share (+55.5% total return).
• ◆AxiomSL's near-monopoly in regulatory capital reporting deepens as Basel IV FRTB (mandatory 2026–2027 implementation deadlines) and DORA (EU Digital Operational Resilience Act) create overlapping compliance waves that extend the high-growth cycle and entrench switching costs, sustaining 15%+ ARR growth well beyond initial consensus expectations.
• ◆The deleverage re-rating is mechanical and high-confidence: $2B+ annual FCF generation drives Net Debt/EBITDA from 3.0x toward 2.0x by FY2027, removing the 'leveraged exchange' discount (19x EV/EBITDA) and re-rating the stock to 'deleveraged financial infrastructure' fair value (20–22x), worth 10–15% in price appreciation independent of any revenue acceleration.

▼ Bear Case

• ◆Basel IV/FRTB implementation cycle peaks in FY2026 and AxiomSL normalizes to 5–7% ARR growth; Murex wins 2–3 major Calypso FRTB platform decisions; combined FinTech ARR growth decelerates to 6–8%, removing the primary EPS growth engine and triggering a market de-rating to 15x EV/EBITDA (exchange utility multiple) — implying ~$63/share (−23.3% total return).
• ◆The $14.3B goodwill balance on the balance sheet creates latent risk: if FinTech ARR growth stalls materially, an Adenza goodwill impairment charge becomes probable — severely damaging management credibility, triggering multiple compression, and signaling acquisition thesis failure.
• ◆Verafin's FIS distribution channel proves slower than expected (FIS banks are sticky to existing compliance vendors), agentic AI monetization attach rates disappoint, and the broader FinTech ARR narrative loses investor confidence — compressing valuation before deleverage benefits are fully realized.

“The central sell-side debate is whether NDAQ's FinTech ARR growth is structural (wide-moat, regulatory-mandate-driven, durable) or cyclical (Basel IV/FRTB implementation spike that normalizes sharply after FY2026–FY2027 deadlines). Consensus models assume FinTech ARR decelerates to 10–12% by FY2027; the bull variant requires the market to recognize that Calypso's FRTB tailwind extends the high-growth cycle — a consensus miss since sell-side focuses on Verafin (the 'AI story') and AxiomSL (the 'monopoly story') while Calypso at $1.2B run-rate growing ~20% YoY quietly drives the bulk of FinTech segment revenue. The secondary debate is whether the deleverage re-rating (19x → 20–22x EV/EBITDA) is already priced at $85, or whether continued leverage reduction through FY2026–FY2027 still provides meaningful multiple expansion. A critical unknown — unresolvable from filings alone — is the Q1 2026 ACV booking breakdown by sub-segment, which would reveal whether Calypso or AxiomSL is driving the reported +50% ACV surge.”

• ◆Q2 FY2026 earnings (July 2026): FinTech ACV booking breakdown by sub-segment (Calypso vs. AxiomSL vs. Verafin) revealing which is driving the +50% ACV surge — the single most important near-term unknown
• ◆Verafin × FIS distribution first quantified conversion data: 300+ incremental bank client additions would signal the AI-enhanced consortium model is succeeding and could accelerate ARR growth from +21% to +25%+
• ◆Net Debt/EBITDA declining below 2.5x milestone: mechanical re-rating trigger removing the 'leveraged exchange' discount and supporting 20–22x EV/EBITDA multiple expansion
• ◆Calypso FRTB platform decision announcements at named Tier 1 banks: win announcements validate the bull case and remove competitive risk; each major win worth $180–240M incremental ARR/year in aggregate
• ◆Basel IV/FRTB regulatory deadline confirmation (2026–2027): mandatory compliance cycle forcing bank platform upgrades extends the FinTech ARR high-growth window beyond current consensus expectations
• ◆23/5 trading regulatory approval timeline: extended trading hours expand volume and listing revenue opportunity; timeline clarity would remove overhang
• ◆Agentic AI premium tier pricing and attach rate disclosure: monetization of AI features at a premium PEPM tier (+15%) is an incremental upside lever not in base case models

• ◆FinTech ARR organic growth decelerates sharply post-Basel IV cycle: if AxiomSL normalizes to 5–7% and Calypso loses major FRTB decisions to Murex, the primary EPS growth engine stalls — triggering Kill Switch #1 (reduce 25%)
• ◆Murex competitive threat in Calypso FRTB platform decisions: Murex/MX.3 is one of only two credible capital markets technology platforms; losing 2+ major named Tier 1 bank decisions in a calendar year removes the bull case catalyst — Kill Switch #4 (reduce 15%)
• ◆Adenza goodwill impairment ($14.3B on balance sheet): any impairment announcement signals acquisition thesis failure and triggers severe multiple compression — Kill Switch #3 (reduce 30%)
• ◆Net Debt/EBITDA trajectory reversal or new large acquisition: deleverage is the most certain near-term re-rating catalyst; any reversal removes this thesis — Kill Switch #2 (reduce 20%)
• ◆CEO Adena Friedman departure or significant insider selling: Friedman is the architect of the Adenza transformation; mid-integration succession uncertainty adds meaningful risk — Kill Switch #5 (reduce 15%)
• ◆Market/AUM cyclicality in exchange and index licensing revenues: QQQ/Nasdaq-100 index licensing is tied to equity market levels; a sustained bear market in AI mega-caps compresses AUM, index revenue, and listings activity
• ◆Integration execution risk: Adenza integration complexity ($10.5B acquisition across three distinct FinTech products) creates operational risk; any system migration failure, customer churn, or synergy shortfall damages both earnings and management credibility